Association of Long-term Antiseizure Medication Use and Incident Type 2 Diabetes Mellitus.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
16 05 2023
16 05 2023
Historique:
received:
07
03
2022
accepted:
09
02
2023
pmc-release:
16
05
2024
medline:
17
5
2023
pubmed:
25
3
2023
entrez:
24
3
2023
Statut:
ppublish
Résumé
Diabetes mellitus (DM) contributes significantly to metabolic syndrome and cardiovascular events, and it may be a comorbidity of epilepsy. The objective of this study was to investigate whether long-term antiseizure medication (ASM) use is associated with the risk of developing type 2 diabetes. We analyzed data from the Chang Gung Research Database. Patients aged ≥45 years who received ASM treatment from January 2001 to May 2019 were identified. Patients with DM-associated diseases and short-term ASM use were excluded. The patients were classified into nonenzyme interaction, enzyme-inducing, enzyme-inhibiting, and mixed ASM groups. The rate of incident diabetes associated with individual ASM was further analyzed. Propensity score weighting was performed to balance between-group differences. Analyses were conducted with Cox proportional regression models and stabilized inverse probability of treatment weighting (IPTW). Hazard ratios (HRs) were calculated at 3, 4, 6, and 9 years after the index date and the end of follow-up. A total of 5,103 patients were analyzed, of whom 474 took nonenzyme interaction ASMs, 1,156 took enzyme-inducing ASMs, 336 took enzyme-inhibiting ASMs, and 3,137 took mixed ASMs. During follow-up (39,248 person-years), 663 patients developed new-onset DM, and the prevalence was 13.0%. The incidence of DM plateaued at 6-9 years after ASM initiation. Enzyme-inhibiting ASMs were significantly associated with a higher HR starting at the third year and then throughout the study period. The HRs were 1.93 (95% CI 1.33-2.80), 1.85 (95% CI 1.24-2.75), and 2.08 (95% CI 1.43-3.03) in unadjusted, adjusted, and stabilized IPTW models, respectively, at the end of follow-up. The dosing of ASM did not increase the risk of DM, and none of the individual ASM analyses reached statistical significance. The long-term use of enzyme-inhibiting ASMs was associated with an increased risk of incident DM, and the risk increased with the duration of treatment. These findings may guide the choice of drugs in those requiring long-term ASM therapy, particularly in high-risk individuals. This study provides Class IV evidence that enzyme-inhibiting ASMs were associated with an increased risk of developing DM compared with nonenzyme interaction ASMs.
Sections du résumé
BACKGROUND AND OBJECTIVES
Diabetes mellitus (DM) contributes significantly to metabolic syndrome and cardiovascular events, and it may be a comorbidity of epilepsy. The objective of this study was to investigate whether long-term antiseizure medication (ASM) use is associated with the risk of developing type 2 diabetes.
METHODS
We analyzed data from the Chang Gung Research Database. Patients aged ≥45 years who received ASM treatment from January 2001 to May 2019 were identified. Patients with DM-associated diseases and short-term ASM use were excluded. The patients were classified into nonenzyme interaction, enzyme-inducing, enzyme-inhibiting, and mixed ASM groups. The rate of incident diabetes associated with individual ASM was further analyzed. Propensity score weighting was performed to balance between-group differences. Analyses were conducted with Cox proportional regression models and stabilized inverse probability of treatment weighting (IPTW). Hazard ratios (HRs) were calculated at 3, 4, 6, and 9 years after the index date and the end of follow-up.
RESULTS
A total of 5,103 patients were analyzed, of whom 474 took nonenzyme interaction ASMs, 1,156 took enzyme-inducing ASMs, 336 took enzyme-inhibiting ASMs, and 3,137 took mixed ASMs. During follow-up (39,248 person-years), 663 patients developed new-onset DM, and the prevalence was 13.0%. The incidence of DM plateaued at 6-9 years after ASM initiation. Enzyme-inhibiting ASMs were significantly associated with a higher HR starting at the third year and then throughout the study period. The HRs were 1.93 (95% CI 1.33-2.80), 1.85 (95% CI 1.24-2.75), and 2.08 (95% CI 1.43-3.03) in unadjusted, adjusted, and stabilized IPTW models, respectively, at the end of follow-up. The dosing of ASM did not increase the risk of DM, and none of the individual ASM analyses reached statistical significance.
DISCUSSION
The long-term use of enzyme-inhibiting ASMs was associated with an increased risk of incident DM, and the risk increased with the duration of treatment. These findings may guide the choice of drugs in those requiring long-term ASM therapy, particularly in high-risk individuals.
CLASSIFICATION OF EVIDENCE
This study provides Class IV evidence that enzyme-inhibiting ASMs were associated with an increased risk of developing DM compared with nonenzyme interaction ASMs.
Identifiants
pubmed: 36963840
pii: WNL.0000000000207222
doi: 10.1212/WNL.0000000000207222
pmc: PMC10186244
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2071-e2082Informations de copyright
© 2023 American Academy of Neurology.
Références
Epilepsy Behav. 2020 May;106:107043
pubmed: 32217418
Diabetes Care. 2013 May;36(5):1422-8
pubmed: 23613602
J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):796-9
pubmed: 23236017
Diabetologia. 2012 Jul;55(7):1985-94
pubmed: 22538358
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Epilepsy Behav. 2020 May;106:106992
pubmed: 32169598
Lancet Neurol. 2012 Sep;11(9):792-802
pubmed: 22832500
CNS Drugs. 2008;22(1):27-47
pubmed: 18072813
Expert Rev Neurother. 2010 Jan;10(1):119-40
pubmed: 20021326
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9232-7
pubmed: 16754860
Int J Prev Med. 2021 Feb 24;12:19
pubmed: 34084316
Biometrics. 2020 Jun;76(2):484-495
pubmed: 31621059
J Am Geriatr Soc. 2016 Oct;64(10):2065-2073
pubmed: 27550392
Seizure. 2014 Oct;23(9):677-84
pubmed: 25028247
Epileptic Disord. 2014 Sep;16(3):333-42
pubmed: 25166266
Drug Saf. 2001;24(13):969-78
pubmed: 11735653
Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2057-2070
pubmed: 30139042
Stat Med. 2014 Mar 30;33(7):1242-58
pubmed: 24122911
Epilepsia. 2010 Feb;51(2):268-73
pubmed: 19682024
Lancet Neurol. 2016 Jan;15(1):106-15
pubmed: 26549780
J Mol Biol. 2020 Mar 6;432(5):1326-1346
pubmed: 31473158
J Child Neurol. 2006 Jan;21(1):70-4
pubmed: 16551457
Prostaglandins Other Lipid Mediat. 2011 Aug;95(1-4):1-10
pubmed: 21757024
Value Health. 2010 Mar-Apr;13(2):273-7
pubmed: 19912596
Epilepsy Behav. 2020 Apr;105:106942
pubmed: 32163888
Biomed J. 2017 Oct;40(5):263-269
pubmed: 29179881
Epilepsy Res. 2007 Jun;75(1):1-9
pubmed: 17499974
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Eur J Neurol. 2012 Sep;19(9):1228-34
pubmed: 22494156
PLoS One. 2020 Oct 29;15(10):e0240907
pubmed: 33120406
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
pubmed: 10902785
Acta Diabetol. 2012 Jun;49(3):167-83
pubmed: 22218826
Stat Med. 2013 Jul 20;32(16):2837-49
pubmed: 23239115
Lancet Psychiatry. 2015 May;2(5):431-451
pubmed: 26360287
JAMA Neurol. 2021 Nov 1;78(11):1367-1374
pubmed: 34605857